Cancer death rates in the United States have been steadily declining despite a concurrent steady rise in cancer diagnoses.1 This is partly driven by innovations in cancer treatment that are providing many patients with prolonged survival. These innovations, however, have introduced new challenges for physicians in managing the toxicities of chronic cancer treatment. One significant toxicity […]

Karen Zaderej, Chairman, CEO, and President at Axogen Inc. discusses the development and commercialization of technologies for peripheral nerve regeneration and repair that can restore nerve function and quality of life to patients using innovative, clinically proven, and economically effective solutions. This allows clinicians to repair damaged nerves more efficiently than current standard-of-care procedures, with fewer potential […]

Athira Pharma, Inc will initiate an open-label extension study for two ongoing clinical trials investigating ATH-1017 to treat Alzheimer’s disease. Both clinical trials — the Phase 2/3 LIFT-AD (NCT04488419) and Phase 2 ACT-AD (NCT04491006) — are investigating ATH-1017, a small molecule designed to enhance the effect of hepatocyte growth factor (HGF), and its receptor, MET. Both are expressed in the central nervous system. […]